Impact of Baseline β-Catenin Comutations on Prognosis in EGFR-Mutant Lung Cancer
CTNNB1 comutations are associated with lower PD-L1 expression and TP53-wt status, correlating with improved outcomes in patients with EGFR-mutant NSCLC undergoing osimertinib therapy. These results suggest that CTNNB1 comutations may serve as a favorable prognostic biomarker in patients with EGFR-mutant NSCLC. Additional prospective studies are warranted to validate these results.
Authors
- Katja Maurus (ORCID: https://orcid.org/0000-0002-3093-3114)
- Petros Christopoulos (ORCID: https://orcid.org/0000-0002-7966-8980)
- Pius Jung
- Julia Doll (ORCID: https://orcid.org/0000-0002-0037-9079)
- Ralf C. Bargou (ORCID: https://orcid.org/0000-0002-1221-7421)
- Andreas Rosenwald
- Elena Hartmann (ORCID: https://orcid.org/0000-0003-2134-2774)
- Jens Kern (ORCID: https://orcid.org/0009-0009-3245-385X)
- Daniel Kazdal (ORCID: https://orcid.org/0000-0001-8187-3281)
- Volker Kunzmann (ORCID: https://orcid.org/0000-0002-3615-7566)
- Simone Reu‐Hofer
- Stephanie Brändlein
- Vivek Venkataramani (ORCID: https://orcid.org/0000-0002-6771-365X)
- Markus Krebs (ORCID: https://orcid.org/0000-0002-1154-0964)
- Manik Chatterjee (ORCID: https://orcid.org/0000-0001-7854-5543)
- Jan Budczies (ORCID: https://orcid.org/0000-0002-6668-5327)
- Julia Böck (ORCID: https://orcid.org/0000-0001-5771-7932)
- Miriam Blasi
- Albrecht Stenzinger
- Maria-Elisabeth Goebeler
- Horst-Dieter Hummel
- Jonas Kulhavy (ORCID: https://orcid.org/0000-0002-8837-1687)
- Valeria Roll (ORCID: https://orcid.org/0000-0003-0804-4107)
Institutions
- University of Augsburg (DE)
- Heidelberg University (DE)
- University of Würzburg (DE)
- University Hospital Heidelberg (DE)
- Comprehensive Cancer Center Mainfranken (DE)
- National Center for Tumor Diseases (DE)
- Universitätsklinikum Würzburg (DE)
- German Center for Lung Research (DE)
- Klinikum Würzburg Mitte (DE)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1200/po-24-00771
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52